These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 36910362)

  • 1. Empagliflozin for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Tang X; Zhang H; Wang X; Yang D
    Afr Health Sci; 2022 Sep; 22(3):391-398. PubMed ID: 36910362
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic outcome of dapagliflozin in patients with type 2 diabetes and non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Hu C; Qu T; Li L; Huang Y; Liu H; Rao C
    Afr Health Sci; 2023 Jun; 23(2):416-421. PubMed ID: 38223613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial.
    Taheri H; Malek M; Ismail-Beigi F; Zamani F; Sohrabi M; Reza Babaei M; Khamseh ME
    Adv Ther; 2020 Nov; 37(11):4697-4708. PubMed ID: 32975679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Empagliflozin on Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.
    Zhang Y; Liu X; Zhang H; Wang X
    Front Endocrinol (Lausanne); 2022; 13():836455. PubMed ID: 35282455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ginger supplementation for the treatment of non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.
    Zhou Q; Peng Y; Chen F; Dai J
    Afr Health Sci; 2023 Mar; 23(1):614-621. PubMed ID: 37545930
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Garlic supplementation for the treatment of chronic liver disease: a meta-analysis of randomized controlled trials.
    Xiaohui L; Jinqi L; Xiaofang X; Zhiqiang S; Renxiu N
    Afr Health Sci; 2023 Jun; 23(2):409-415. PubMed ID: 38223588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial.
    Sattar N; Fitchett D; Hantel S; George JT; Zinman B
    Diabetologia; 2018 Oct; 61(10):2155-2163. PubMed ID: 30066148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial.
    Chehrehgosha H; Sohrabi MR; Ismail-Beigi F; Malek M; Reza Babaei M; Zamani F; Ajdarkosh H; Khoonsari M; Fallah AE; Khamseh ME
    Diabetes Ther; 2021 Mar; 12(3):843-861. PubMed ID: 33586120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials.
    Sun L; Deng C; Gu Y; He Y; Yang L; Shi J
    Clin Res Hepatol Gastroenterol; 2022 Apr; 46(4):101876. PubMed ID: 35321843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-Alcoholic Fatty Liver Disease: A Meta-Analysis of Randomized Controlled Trials.
    He XX; Wu XL; Chen RP; Chen C; Liu XG; Wu BJ; Huang ZM
    PLoS One; 2016; 11(10):e0162368. PubMed ID: 27711128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Off-Label Therapy for Non-alcoholic Fatty Liver Disease in Improving Non-invasive and Invasive Biomarkers: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials.
    Luo Q; Wei R; Cai Y; Zhao Q; Liu Y; Liu WJ
    Front Med (Lausanne); 2022; 9():793203. PubMed ID: 35280867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of dietary polyphenol supplementation in the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Yang K; Chen J; Zhang T; Yuan X; Ge A; Wang S; Xu H; Zeng L; Ge J
    Front Immunol; 2022; 13():949746. PubMed ID: 36159792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial).
    Kuchay MS; Krishan S; Mishra SK; Farooqui KJ; Singh MK; Wasir JS; Bansal B; Kaur P; Jevalikar G; Gill HK; Choudhary NS; Mithal A
    Diabetes Care; 2018 Aug; 41(8):1801-1808. PubMed ID: 29895557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease.
    Shimizu M; Suzuki K; Kato K; Jojima T; Iijima T; Murohisa T; Iijima M; Takekawa H; Usui I; Hiraishi H; Aso Y
    Diabetes Obes Metab; 2019 Feb; 21(2):285-292. PubMed ID: 30178600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term empagliflozin therapy improves levels of hepatic fibrosis marker in patients with non-alcoholic fatty liver disease complicated by type 2 diabetes mellitus.
    Shinozaki S; Tahara T; Lefor AK; Ogura M
    J Med Invest; 2020; 67(3.4):280-284. PubMed ID: 33148902
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of empagliflozin on markers of liver steatosis and fibrosis and their relationship to cardiorenal outcomes.
    Kahl S; Ofstad AP; Zinman B; Wanner C; Schüler E; Sattar N; Inzucchi SE; Roden M
    Diabetes Obes Metab; 2022 Jun; 24(6):1061-1071. PubMed ID: 35166009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of different natural products in patients with non-alcoholic fatty liver disease-A network meta-analysis of randomized controlled trials.
    Liu H; Li Y; Jin Y; Li X; Wang D; Yu X; Jiang Z; Yin G; Chen S; Zhang X; Meng D; Yu W; Jiang W; Zhang F
    Phytother Res; 2024 Jul; 38(7):3801-3824. PubMed ID: 38886838
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of metformin administration on liver enzymes and body composition in non-diabetic patients with non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis: An up-to date systematic review and meta-analysis of randomized controlled trials.
    Jalali M; Rahimlou M; Mahmoodi M; Moosavian SP; Symonds ME; Jalali R; Zare M; Imanieh MH; Stasi C
    Pharmacol Res; 2020 Sep; 159():104799. PubMed ID: 32278041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of controlled attenuation parameter (CAP) and liver stiffness measurement (LSM) for assessing steatosis and fibrosis in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
    Cao YT; Xiang LL; Qi F; Zhang YJ; Chen Y; Zhou XQ
    EClinicalMedicine; 2022 Sep; 51():101547. PubMed ID: 35844772
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does turmeric/curcumin supplementation improve serum alanine aminotransferase and aspartate aminotransferase levels in patients with nonalcoholic fatty liver disease? A systematic review and meta-analysis of randomized controlled trials.
    Goodarzi R; Sabzian K; Shishehbor F; Mansoori A
    Phytother Res; 2019 Mar; 33(3):561-570. PubMed ID: 30653773
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.